CORE 015: Clinical Protocol and Data Management; Data and Safety Monitoring; Inclusion of Women, Minorities and Children Project Summary The VICC Clinical Trials Shared Resource (CTSR) serves as a comprehensive resource to support adult and pediatric clinical research of the Cancer Center members ensuring timely and accurate protocol management. The CTSR continuously evaluates its systems to respond to the ever-changing landscape of clinical research now emphasizing increasingly complex genotype-driven trials. The CTSR assists investigators in all portions of clinical trial (CT) management, including financial, regulatory, data, screening, nursing management, imaging support and sample processing. The CTSR has dedicated budget and contracting analysts to negotiate budgets and contracts; regulatory staff to assist in preparation of all regulatory documents, including submissions to the Scientific Review Committee (SRC), the IRB, the Clinical Research Center (CRC), and IND submissions to the FDA. Scientific review, budgeting and contracting and regulatory submission occur in parallel, leading to an average time to final contract and Institutional Review Board (IRB) approval of 94 calendar days. Research staff report protocol deviations and Serious Adverse Event (SAE), while providing a robust data management team for all CTs. Additionally, Research Nurses support Investigators in the day-to-day protocol implementation, including consenting and patient visits. In response to the increasing complexity of biospecimen requirements, the Clinical Trial Processing Laboratory underwent a major redesign and is now processing more than 1100 specimens per month. The CTSR assists in patient accrual by screening new patients for CT eligibility and interacting with referring physicians to identify potential studies for them. VICC places highest priority on ensuring the safety of our patients participating in clinical research and provides a compliance team who performs monitoring and internal audits as outlined by the Data and Safety Monitoring Committee (DSMC). Additionally, CTSR provides investigator support for study registration and results reporting to ClinicalTrials.gov and the NCI Clinical Trials Reporting Program. Continuing its commitment to increasing diversity in clinical trials, VICC supported the recruitment of several key faculty whose work focuses on disparities and community engagement in clinical research. Since 2010, VICC sustained a 37% increase in accruals to interventional trials (699 to 961) and a 15% increase in therapeutic trials (581 to 666). Under the direction of the Medical Director, Vicki Keedy, MD, MSCI and the Director, Debra Wujcik, PhD, RN, the CTSR assists faculty in performing a large portfolio of CTs bringing innovative discoveries from the laboratory to clinical care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-23
Application #
9553522
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
23
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Bloodworth, Melissa H; Rusznak, Mark; Pfister, Connor C et al. (2018) Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology. J Allergy Clin Immunol 142:683-687.e12
Saito-Diaz, Kenyi; Benchabane, Hassina; Tiwari, Ajit et al. (2018) APC Inhibits Ligand-Independent Wnt Signaling by the Clathrin Endocytic Pathway. Dev Cell 44:566-581.e8
Cardin, Dana B; Thota, Ramya; Goff, Laura W et al. (2018) A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Am J Clin Oncol 41:772-776
Hormuth 2nd, David A; Weis, Jared A; Barnes, Stephanie L et al. (2018) Biophysical Modeling of In Vivo Glioma Response After Whole-Brain Radiation Therapy in a Murine Model of Brain Cancer. Int J Radiat Oncol Biol Phys 100:1270-1279
Rojas, Juan D; Lin, Fanglue; Chiang, Yun-Chen et al. (2018) Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. Theranostics 8:141-155
Dutter, Brendan F; Ender, Anna; Sulikowski, Gary A et al. (2018) Rhodol-based thallium sensors for cellular imaging of potassium channel activity. Org Biomol Chem 16:5575-5579
Vierra, Nicholas C; Dickerson, Matthew T; Jordan, Kelli L et al. (2018) TALK-1 reduces delta-cell endoplasmic reticulum and cytoplasmic calcium levels limiting somatostatin secretion. Mol Metab 9:84-97
Schlegel, Cameron; Weis, Victoria G; Knowles, Byron C et al. (2018) Apical Membrane Alterations in Non-intestinal Organs in Microvillus Inclusion Disease. Dig Dis Sci 63:356-365
Lewis Jr, James S; Shelton, Jeremy; Kuhs, Krystle Lang et al. (2018) p16 Immunohistochemistry in Oropharyngeal Squamous Cell Carcinoma Using the E6H4 Antibody Clone: A Technical Method Study for Optimal Dilution. Head Neck Pathol 12:440-447
Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858

Showing the most recent 10 out of 2462 publications